Developing a marketable FibroSelect platform for bespoke viral vector purifications

Gene therapy is an exciting new wave of medicine whereby therapeutic DNA is delivered into patients' cells to correct genetic disorders, use the body's own cells to make therapeutic proteins, or empower one's immune system to better fight cancer. Development of these advanced therapies is however still at a relatively early stage and current manufacturing processes remain prohibitively expensive. This expense is due in part to inefficient production and purification of the viral vectors that are primarily used to deliver genetic packages into patients' cells. The transformative promise of these therapies will not be realised if they cannot be mass manufactured to produce a therapy that is affordable to healthcare providers such as the NHS. Puridify has been working with several clinical stage companies over the last 3 years to develop a breakthrough purification technology based on nanofibres. This project will allow Puridify to demonstrate the ability to tailor this purification platform for gene therapy developers; providing the lower cost, more efficient and scalable manufacturing processes required to deliver affordable gene therapies to patients.